ISSN:

ジャーナル・オブ・オンコロジーの研究と治療

オープンアクセス

当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

The Importance of a Multi-Disciplinary Approach for Managing the Soft-tissue Sarcomas of Extremities:A Practical Case from the Sarcoma Team of CHU HASSAN II, Fez

Mazti Asmae, El Koubaiti ghizlane, El Idrissi Mohamed, El Ibrahimi Abdelhalim, EL Maaroufi Mustapha, El Fakir Samira, Arifi Samia, Bouhafa Touria, Mrini Abdelmajid and Chbani Laila

Introduction: Soft tissue sarcomas are malignant tumors that require management in specialized centers. The aim of our study is to evaluate the benefit of the multidisciplinary meeting (RCM) on the management of these tumors.

Materials and methods: It is a prospective study, which is conducted in the HASSAN II University Hospital Center in Fez. This research project has lasted for a period of 28 months.

Results: ninety-seven (97) cases were selected, the average age was 52 years. The lower limb is the most frequent site (77%) with deep localization in 92.8% of cases. Eighty-two patients (88%) have had a prior biopsy. Seventy-three patients (75.3%) have received MRI before surgery. Fifty-six patients were operated, with R0 resection in 34 patients, R1 in 16 patients and R2 in 6 patients. Liposarcomas were the most frequent (26.5%), followed by synovialosarcomas (14.4%), leiomyosarcomas (10.3%) and undifferentiated pleomorphic sarcomas (10.3%). Neoadjuvant chemotherapy was indicated in 30 patients. Adjuvant chemotherapy or radiotherapy was indicated in 22 patients. The overall survival rate was 15.19 months, with a significant improvement in survival in patients with multidisciplinary management.

Conclusion: The presented data are similar to the literature one with respect to the interest of multidisciplinary management of soft tissue sarcomas, specifically on the prognosis and survival of patients.

免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません。